World Investment Advisors Reduces Stock Holdings in Guardant Health, Inc. $GH

World Investment Advisors lowered its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 26.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,909 shares of the company’s stock after selling 4,381 shares during the quarter. World Investment Advisors’ holdings in Guardant Health were worth $1,100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of GH. Algert Global LLC boosted its stake in Guardant Health by 169.1% in the third quarter. Algert Global LLC now owns 120,114 shares of the company’s stock valued at $7,505,000 after acquiring an additional 75,474 shares in the last quarter. Iron Triangle Partners LP lifted its holdings in shares of Guardant Health by 33.3% in the 3rd quarter. Iron Triangle Partners LP now owns 400,000 shares of the company’s stock valued at $24,992,000 after purchasing an additional 100,000 shares during the last quarter. Capricorn Fund Managers Ltd boosted its position in shares of Guardant Health by 197.8% in the 4th quarter. Capricorn Fund Managers Ltd now owns 107,787 shares of the company’s stock valued at $11,009,000 after purchasing an additional 71,587 shares during the period. HighVista Strategies LLC grew its stake in Guardant Health by 128.5% during the 3rd quarter. HighVista Strategies LLC now owns 64,583 shares of the company’s stock worth $4,035,000 after buying an additional 36,318 shares during the last quarter. Finally, Atika Capital Management LLC lifted its stake in Guardant Health by 49.1% in the third quarter. Atika Capital Management LLC now owns 133,000 shares of the company’s stock valued at $8,310,000 after buying an additional 43,800 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

GH stock opened at $156.17 on Thursday. The stock has a market capitalization of $20.71 billion, a PE ratio of -46.07 and a beta of 1.59. The company has a fifty day moving average of $124.35 and a 200-day moving average of $107.49. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $174.08.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Piper Sandler set a $127.00 target price on shares of Guardant Health in a report on Thursday, May 21st. Sanford C. Bernstein increased their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. Royal Bank Of Canada started coverage on Guardant Health in a report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price target on the stock. Bank of America boosted their price target on Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. upped their price objective on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $153.74.

Insider Transactions at Guardant Health

In other Guardant Health news, CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $128.62, for a total transaction of $257,240.00. Following the transaction, the chief financial officer owned 47,509 shares in the company, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the sale, the director directly owned 11,048 shares of the company’s stock, valued at $1,449,055.68. This represents a 15.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,681 shares of company stock valued at $90,566,438 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.